Isomorphic Labs, the drug-discovery company Alphabet spun out of Google DeepMind in 2021, said on 17 November 2026 that it has closed a $5 billion Series C. Greenoaks and Sequoia Capital co-led it, and Alphabet made what was called a significant investment through its GV and CapitalG funds.
“Our drug design engine is generating molecules with unprecedented precision and speed”
Demis Hassabis, Isomorphic Labs chief executive, in the announcement, as SiliconANGLE reported · siliconangle.com ↗
Andreessen Horowitz joined as a new investor, alongside existing backers Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. No valuation was announced, though Bloomberg reported talks at about $50 billion on 4 November. It comes six months after a $2.1 billion Series B, and one outlet counts $7.7 billion disclosed across three rounds since March 2025.

Landscape artwork on Isomorphic Labs' own Series C announcement page
Isomorphic Labs · Image: Isomorphic Labs
Demis Hassabis, the chief executive, says the company's engine is turning out molecules faster and more accurately than before, and that the money will go to biology models and to moving its first therapeutic programmes toward trials. That engine, IsoDDE, is used by several pharmaceutical firms. Eli Lilly and Novartis signed deals in January 2024, and Johnson & Johnson followed in January 2026.
About Isomorphic Labs
Isomorphic Labs is a London-based AI drug-discovery company founded by Demis Hassabis. It was incorporated on 24 February 2021 as an Alphabet spin-off from DeepMind, and its work builds on DeepMind's AlphaFold protein-structure model.
Its outside funding began in 2025. It raised $600 million in a first external round led by Thrive Capital, which Wikipedia dates to April 2025 while two outlets say March. On 12 May 2026 it announced a $2.1 billion Series B, again led by Thrive Capital, a little under a year later.
1
Models indexed
Models on AIPopDB
The pipeline is still preclinical. Isomorphic claims early positive results in oncology and immunology but has shown no data and has given no new date for first dosing. The BioIndustry Association warned that megadeals can mask how hard early-stage funding remains.
